Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
{{output}}
BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abirat... ...
